Travere Therapeutics Inc. (TVTX)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to s...

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS.

The stock market is attempting to rebound amid President Donald Trump's trade war. The post Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles appeared first on Investor...

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and...

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim...

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago.

Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for s...

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.